Skip to main content

Table 1 Baseline demographic and patient characteristics

From: Predicting hospital admission and discharge with symptom or function scores in patients with schizophrenia: pooled analysis of a clinical trial extension

Parameter Statistics
  Not hospitalized at start of the open-label phase Hospitalized at start of the open-label phase
Age, years   
n 646 382
Mean (SD) 37.8 (11.0) 37.3 (10.9)
Median (range) 38.0 (18.0; 76.0) 36.0 (18.0; 66.0)
Age groups, n (%)   
18 to < 35 278 (43.0) 169 (44.2)
35 to < 55 322 (49.8) 191 (50.0)
≥ 55 46 (7.1) 22 (5.8)
Gender, n (%)   
Female 254 (39.3) 165 (43.2)
Male 392 (60.7) 217 (56.8)
Schizophrenia duration, n (%)   
0 to < 4 years 166 (25.7) 92 (24.1)
4 to < 10 years 189 (29.3) 121 (31.7)
≥ 10 years (includes 2 missing) 291 (45.0) 168 (44.0)
Study country, n (%)   
US 198 (30.7) 34 (8.9)
Non-US 448 (69.3) 348 (91.1)
Remaining in trial, n (%)   
Week 1 646 (100.0) 382 (100.0)
Week 4 646 (100.0) 382 (100.0)
Week 8 563 (87.2) 315 (82.5)
Week 12 522 (80.8) 286 (74.9)
Week 16 490 (75.9) 263 (68.8)
Week 20 473 (73.2) 252 (66.0)
Week 24 446 (69.0) 242 (63.4)
Week 28 414 (64.1) 229 (59.9)
Week 32 400 (61.9) 222 (58.1)
Week 36 379 (58.70 210 (55.0)
Week 40 365 (56.5) 202 (52.9)
Week 44 354 (54.8) 193 (50.5)
Week 48 335 (51.9) 189 (49.5)
Week 52 319 (49.4) 187 (49.0)